Equities

Cabaletta Bio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CABA:NSQ

Cabaletta Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.51
  • Today's Change0.18 / 7.73%
  • Shares traded2.37m
  • 1 Year change-3.46%
  • Beta3.3051
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy4
Outperform4
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Cabaletta Bio Inc have a median target of 14.00, with a high estimate of 30.00 and a low estimate of 2.00. The median estimate represents a 457.77% increase from the last price of 2.51.
High1,095.2%30.00
Med457.8%14.00
Low-20.3%2.00

Earnings history & estimates in USD

On Oct 27, 2025, Cabaletta Bio Inc reported 3rd quarter 2025 losses of -0.44 per share. This result exceeded the -0.47 consensus loss of the 9 analysts covering the company and exceeded last year's 3rd quarter results by 29.03%.
The next earnings announcement is expected on Mar 30, 2026.
Average growth rate+5.71%
Cabaletta Bio Inc reported annual 2024 losses of -2.34 per share on Mar 31, 2025.
Average growth rate-14.63%
More ▼

Revenue history & estimates in USD

Cabaletta Bio, Inc. did not report revenues for the 3rd quarter 2025. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Cabaletta Bio, Inc. did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.